Patents by Inventor Jose F. Rojas
Jose F. Rojas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11932859Abstract: Methods are provided herein for assembling at least two nucleic acids using a sequence specific nuclease agent (e.g., a gRNA-Cas complex) to create end sequences having complementarity and subsequently assembling the overlapping complementary sequences. The nuclease agent (e.g., a gRNA-Cas complex) can create double strand breaks in dsDNA in order to create overlapping end sequences or can create nicks on each strand to produce complementary overhanging end sequences. Assembly using the method described herein can assemble any nucleic acids having overlapping sequences or can use a joiner oligo to assemble sequences without complementary ends.Type: GrantFiled: March 11, 2020Date of Patent: March 19, 2024Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Chris Schoenherr, John McWhirter, Corey Momont, Caitlin L. Goshert, Lynn Macdonald, Gregg S. Warshaw, Jose F. Rojas, Ka-Man Venus Lai, David M. Valenzuela, Andrew J. Murphy
-
Publication number: 20230189772Abstract: Genetically modified non-human animals comprising a humanized interleukin-15 (IL-15) gene. Cells, embryos, and non-human animals comprising a human IL-15 gene. Rodents that express humanized or human IL-15 protein.Type: ApplicationFiled: October 17, 2022Publication date: June 22, 2023Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Jose F. Rojas, Ka-Man Venus Lai, Andrew J. Murphy, Cagan Gurer
-
Patent number: 11503813Abstract: Genetically modified non-human animals comprising a humanized interleukin-15 (IL-15) gene. Cells, embryos, and non-human animals comprising a human IL-15 gene. Rodents that express humanized or human IL-15 protein.Type: GrantFiled: January 2, 2020Date of Patent: November 22, 2022Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Jose F. Rojas, Ka-Man Venus Lai, Andrew J. Murphy, Cagan Gurer
-
Patent number: 11499164Abstract: Methods for introducing a scarless targeted genetic modification into a preexisting targeting vector are provided. The methods can use combinations of bacterial homologous recombination (BHR) and in vitro assembly to introduce such targeted genetic modifications into a preexisting targeting vector in a scarless manner.Type: GrantFiled: April 30, 2021Date of Patent: November 15, 2022Assignee: Regeneran Pharmaceuticals, Inc.Inventors: Susannah Brydges, Jose F. Rojas, Gregg S. Warshaw, Chia-Jen Siao
-
Patent number: 11111504Abstract: Methods for introducing a scarless targeted genetic modification into a preexisting targeting vector are provided. The methods can use combinations of bacterial homologous recombination (BHR) and in vitro assembly to introduce such targeted genetic modifications into a preexisting targeting vector in a scarless manner.Type: GrantFiled: April 2, 2020Date of Patent: September 7, 2021Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Susannah Brydges, Jose F. Rojas, Gregg S. Warshaw, Chia-Jen Siao
-
Publication number: 20210254099Abstract: Methods for introducing a scarless targeted genetic modification into a preexisting targeting vector are provided. The methods can use combinations of bacterial homologous recombination (BHR) and in vitro assembly to introduce such targeted genetic modifications into a preexisting targeting vector in a scarless manner.Type: ApplicationFiled: April 30, 2021Publication date: August 19, 2021Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Susannah Brydges, Jose F. Rojas, Gregg S. Warshaw, Chia-Jen Siao
-
Publication number: 20210227812Abstract: Non-human animal genomes, non-human animal cells, and non-human animals comprising a humanized PNPLA3 locus and methods of making and using such non-human animal genomes, non-human animal cells, and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized PNPLA3 locus express a human PNPLA3 protein or a chimeric PNPLA3 protein, fragments of which are from human PNPLA3. Methods are provided for using such non-human animals comprising a humanized PNPLA3 locus to assess in vivo efficacy of human-PNPLA3-targeting reagents such as nuclease agents designed to target human PNPLA3.Type: ApplicationFiled: January 27, 2021Publication date: July 29, 2021Inventors: Xiping Cheng, Jose F. Rojas, Mark Sleeman
-
Publication number: 20200318134Abstract: Methods for introducing a scarless targeted genetic modification into a preexisting targeting vector are provided. The methods can use combinations of bacterial homologous recombination (BHR) and in vitro assembly to introduce such targeted genetic modifications into a preexisting targeting vector in a scarless manner.Type: ApplicationFiled: April 2, 2020Publication date: October 8, 2020Inventors: Susannah Brydges, Jose F. Rojas, Gregg S. Warshaw, Chia-Jen Siao
-
Publication number: 20200208161Abstract: Methods are provided herein for assembling at least two nucleic acids using a sequence specific nuclease agent (e.g., a gRNA-Cas complex) to create end sequences having complementarity and subsequently assembling the overlapping complementary sequences. The nuclease agent (e.g., a gRNA-Cas complex) can create double strand breaks in dsDNA in order to create overlapping end sequences or can create nicks on each strand to produce complementary overhanging end sequences. Assembly using the method described herein can assemble any nucleic acids having overlapping sequences or can use a joiner oligo to assemble sequences without complementary ends.Type: ApplicationFiled: March 11, 2020Publication date: July 2, 2020Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: Chris Schoenherr, John McWhirter, Corey Momont, Caitlin L. Goshert, Lynn Macdonald, Gregg S. Warshaw, Jose F. Rojas, Ka-Man Venus Lai, David M. Valenzuela, Andrew J. Murphy
-
Publication number: 20200178508Abstract: Genetically modified non-human animals comprising a humanized interleukin-15 (IL-15) gene. Cells, embryos, and non-human animals comprising a human IL-15 gene. Rodents that express humanized or human IL-15 protein.Type: ApplicationFiled: January 2, 2020Publication date: June 11, 2020Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Jose F. Rojas, Ka-Man Venus Lai, Andrew J. Murphy, Cagan Gurer
-
Patent number: 10626402Abstract: Methods are provided herein for assembling at least two nucleic acids using a sequence specific nuclease agent (e.g., a gRNA-Cas complex) to create end sequences having complementarity and subsequently assembling the overlapping complementary sequences. The nuclease agent (e.g., a gRNA-Cas complex) can create double strand breaks in dsDNA in order to create overlapping end sequences or can create nicks on each strand to produce complementary overhanging end sequences. Assembly using the method described herein can assemble any nucleic acids having overlapping sequences or can use a joiner oligo to assemble sequences without complementary ends.Type: GrantFiled: March 7, 2019Date of Patent: April 21, 2020Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Chris Schoenherr, John McWhirter, Corey Momont, Caitlin L. Goshert, Lynn MacDonald, Gregg S. Warshaw, Jose F. Rojas, Ka-Man Venus Lai, David M. Valenzuela, Andrew J. Murphy
-
Patent number: 10561125Abstract: Genetically modified non-human animals comprising a humanized interleukin-15 (IL-15) gene. Cells, embryos, and non-human animals comprising a human IL-15 gene. Rodents that express humanized or human IL-15 protein.Type: GrantFiled: December 6, 2017Date of Patent: February 18, 2020Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Jose F. Rojas, Ka-Man Venus Lai, Andrew J. Murphy, Cagan Gurer
-
Publication number: 20190194668Abstract: Methods are provided herein for assembling at least two nucleic acids using a sequence specific nuclease agent (e.g., a gRNA-Cas complex) to create end sequences having complementarity and subsequently assembling the overlapping complementary sequences. The nuclease agent (e.g., a gRNA-Cas complex) can create double strand breaks in dsDNA in order to create overlapping end sequences or can create nicks on each strand to produce complementary overhanging end sequences. Assembly using the method described herein can assemble any nucleic acids having overlapping sequences or can use a joiner oligo to assemble sequences without complementary ends.Type: ApplicationFiled: March 7, 2019Publication date: June 27, 2019Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: Chris Schoenherr, John McWhirter, Corey Momont, Caitlin Montagna, Lynn Macdonald, Gregg S. Warshaw, Jose F. Rojas, Ka-Man Venus Lai, David M. Valenzuela, Andrew J. Murphy
-
Publication number: 20190141966Abstract: Non-human animal genomes, non-human animal cells, and non-human animals comprising a mutated Slc30a8 locus and methods of making and using such non-human animal genomes, non-human animal cells, and non-human animals are provided. The non-human animals can have increased insulin secretory capacity.Type: ApplicationFiled: November 9, 2018Publication date: May 16, 2019Inventors: Sandra Kleiner, Jose F. Rojas, Jesper Gromada
-
Patent number: 10273488Abstract: Methods are provided herein for assembling at least two nucleic acids using a sequence specific nuclease agent (e.g., a gRNA-Cas complex) to create end sequences having complementarity and subsequently assembling the overlapping complementary sequences. The nuclease agent (e.g., a gRNA-Cas complex) can create double strand breaks in dsDNA in order to create overlapping end sequences or can create nicks on each strand to produce complementary overhanging end sequences. Assembly using the method described herein can assemble any nucleic acids having overlapping sequences or can use a joiner oligo to assemble sequences without complementary ends.Type: GrantFiled: June 30, 2017Date of Patent: April 30, 2019Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Chris Schoenherr, John McWhirter, Corey Momont, Caitlin Montagna, Lynn Macdonald, Gregg S. Warshaw, Jose F. Rojas, Ka-Man Venus Lai, David M. Valenzuela, Andrew J. Murphy
-
Publication number: 20180116192Abstract: Genetically modified non-human animals comprising a humanized interleukin-15 (IL-15) gene. Cells, embryos, and non-human animals comprising a human IL-15 gene. Rodents that express humanized or human IL-15 protein.Type: ApplicationFiled: December 6, 2017Publication date: May 3, 2018Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Jose F. Rojas, Ka-Man Venus Lai, Andrew J. Murphy, Cagan Gurer
-
Publication number: 20180002708Abstract: Methods are provided herein for assembling at least two nucleic acids using a sequence specific nuclease agent (e.g., a gRNA-Cas complex) to create end sequences having complementarity and subsequently assembling the overlapping complementary sequences. The nuclease agent (e.g., a gRNA-Cas complex) can create double strand breaks in dsDNA in order to create overlapping end sequences or can create nicks on each strand to produce complementary overhanging end sequences. Assembly using the method described herein can assemble any nucleic acids having overlapping sequences or can use a joiner oligo to assemble sequences without complementary ends.Type: ApplicationFiled: June 30, 2017Publication date: January 4, 2018Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Chris Schoenherr, John McWhirter, Corey Momont, Caitlin Montagna, Lynn Macdonald, Gregg S. Warshaw, Jose F. Rojas, Ka-Man Venus Lai, David M. Valenzuela, Andrew J. Murphy
-
Patent number: 9738897Abstract: Methods are provided herein for assembling at least two nucleic acids using a sequence specific nuclease agent (e.g., a gRNA-Cas complex) to create end sequences having complementarity and subsequently assembling the overlapping complementary sequences. The nuclease agent (e.g., a gRNA-Cas complex) can create double strand breaks in dsDNA in order to create overlapping end sequences or can create nicks on each strand to produce complementary overhanging end sequences. Assembly using the method described herein can assemble any nucleic acids having overlapping sequences or can use a joiner oligo to assemble sequences without complementary ends.Type: GrantFiled: June 23, 2015Date of Patent: August 22, 2017Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Chris Schoenherr, John McWhirter, Corey Momont, Caitlin Montagna, Lynn Macdonald, Gregg S. Warshaw, Jose F. Rojas, Ka-Man Venus Lai, David M. Valenzuela, Andrew J. Murphy
-
Patent number: 9580715Abstract: Methods are provided herein for assembling at least two nucleic acids using a sequence specific nuclease agent (e.g., a gRNA-Cas complex) to create end sequences having complementarity and subsequently assembling the overlapping complementary sequences. The nuclease agent (e.g., a gRNA-Cas complex) can create double strand breaks in dsDNA in order to create overlapping end sequences or can create nicks on each strand to produce complementary overhanging end sequences. Assembly using the method described herein can assemble any nucleic acids having overlapping sequences or can use a joiner oligo to assemble sequences without complementary ends.Type: GrantFiled: October 29, 2015Date of Patent: February 28, 2017Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Chris Schoenherr, John McWhirter, Corey Momont, Caitlin Montagna, Lynn Macdonald, Gregg S. Warshaw, Jose F. Rojas, Ka-Man Venus Lai, David M. Valenzuela, Andrew J. Murphy
-
Publication number: 20160115486Abstract: Methods are provided herein for assembling at least two nucleic acids using a sequence specific nuclease agent (e.g., a gRNA-Cas complex) to create end sequences having complementarity and subsequently assembling the overlapping complementary sequences. The nuclease agent (e.g., a gRNA-Cas complex) can create double strand breaks in dsDNA in order to create overlapping end sequences or can create nicks on each strand to produce complementary overhanging end sequences. Assembly using the method described herein can assemble any nucleic acids having overlapping sequences or can use a joiner oligo to assemble sequences without complementary ends.Type: ApplicationFiled: October 29, 2015Publication date: April 28, 2016Inventors: Chris Schoenherr, John McWhirter, Corey Momont, Lynn Macdonald, Andrew J. Murphy, Gregg S. Warshaw, Jose F. Rojas, Ka-Man Venus Lai, David M. Valenzuela, Caitlin Montagna